Adaptive Immunity

Adaptive Immunity describes antigen-specific immune responses mediated by lymphocytes that develop over days to weeks following antigen encounter, generating immunological memory enabling faster, stronger responses upon re-exposure. This arm of the immune system comprises B cells producing antibodies and T cells providing cellular immunity, both recognising antigens through clonally expressed receptors.

The biopharmaceutical industry leverages adaptive immunity in vaccine development, immunotherapy, and autoimmune disease treatment. Vaccines prime adaptive immune memory establishing durable protection. Checkpoint inhibitors reinvigorate exhausted adaptive immune cells against tumours. Autoimmune therapies selectively modulate aberrant adaptive responses causing tissue damage. Biomarker development monitors adaptive immune activation as pharmacodynamic evidence of therapeutic effect. As mechanistic understanding of adaptive immune regulation deepens, precision immunotherapy approaches advance through targeted modulation of specific lymphocyte populations.